With this acquisition Scantox has nearly 200 employees across four sites.

“Scantox embarked on an ambitious growth journey when we acquired the first two international companies last year, and we are thrilled to now expand our Group further with the acquisition of Q&Q. We welcome a company known for their solid expertise within the field of bioanalysis. This aligns perfectly with the current and future direction of Scantox, where a constant focus on the highest scientific and technical quality, as well as ethical standards, is at the core. The new expansion will make us well positioned to meet current and future market requirements, as a preferred service provider and partner to our growing customer portfolio of pharma, biotech, and medical device companies, paving the way for strong continued profitable growth,” says Jeanet Løgsted, CEO of Scantox.

Tailor made bioanalytical services

Gothenburg-based contract lab Q&Q is a provider of tailor made bioanalytical services and brings a highly complementary service offering to Scantox’s stronghold in pharmacology and regulatory toxicology.

“We are looking forward to leveraging the synergies across Scantox to deliver the best customized solutions to the market. Our expertise and set up will fit very well into the Scantox portfolio, and I am convinced that current and new customers will benefit from the full service offering for their pre-clinical development requirements,” says Rickard Wahlström, CEO of Q&Q.

Q&Q was founded in 2011 and is located at the BioVentureHub at Astra Zeneca. Core business capabilities include characterization and quantitatification of organic compounds using chromatography and mass spectrometry. Services are based on customer specific method development requirements or standard methodology (e.g. Ph.Eur.), and analyses can be performed according to GMP, GLP and GCLP depending on customer requirements.

An important step in the execution of the company’s long-term growth strategy

Scantox is a Nordic pre-clinical GLP-accredited CRO, focused on pharmacology and regulatory toxicology and headquartered in Denmark. Founded in 1977, Scantox is today owned by Impilo, a Nordic healthcare investment company.

“Scantox is experiencing strong momentum following the transition into an independent company in 2021, and this acquisition is another important step in the execution of the company’s long-term growth strategy. Impilo remains excited about the future potential in the sector and looks forward to continuing working with Scantox to further expand its portfolio of services and to strengthen its position globally,” says Nicholas Hooge, Partner at Impilo.

Scantox is a partner for product development services within the pharmaceutical, biotech and medical devices industries, with a world known expertise within the Göttingen minipigs.

Photo of Jeanet Løgsted, CEO Scantox Group